Does the media refer more to MDCX or SBFM?

In the previous week, Sunshine Biopharma had 1 more articles in the media than Medicus Pharma. MarketBeat recorded 3 mentions for Sunshine Biopharma and 2 mentions for Medicus Pharma. Medicus Pharma's average media sentiment score of 0.93 beat Sunshine Biopharma's score of 0.73 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer SBFM or CTXR?

In the previous week, Citius Pharmaceuticals had 8 more articles in the media than Sunshine Biopharma. MarketBeat recorded 11 mentions for Citius Pharmaceuticals and 3 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.73 beat Citius Pharmaceuticals' score of -0.46 indicating that Sunshine Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SBFM or INTS?

In the previous week, Intensity Therapeutics had 9 more articles in the media than Sunshine Biopharma. MarketBeat recorded 12 mentions for Intensity Therapeutics and 3 mentions for Sunshine Biopharma. Intensity Therapeutics' average media sentiment score of 0.96 beat Sunshine Biopharma's score of 0.73 indicating that Intensity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADIL or SBFM?

In the previous week, Sunshine Biopharma had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 3 mentions for Sunshine Biopharma and 2 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.94 beat Sunshine Biopharma's score of 0.73 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Sunshine Biopharma (SBFM) Competitors

$1.24 +0.10 (+8.77%)

As of 04:00 PM Eastern

Compare

SBFM vs. MDCX, CTXR, SCNX, INTS, and ADIL

Should you buy Sunshine Biopharma stock or one of its competitors? Sunshine Biopharma's main competitors and comparable companies include Medicus Pharma (MDCX), Citius Pharmaceuticals (CTXR), Scienture (SCNX), Intensity Therapeutics (INTS), and Adial Pharmaceuticals (ADIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sunshine Biopharma compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Medicus Pharma presently has a consensus target price of $9.00, indicating a potential upside of 3,251.96%. Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 5,545.16%. Given Sunshine Biopharma's higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Medicus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sunshine Biopharma had 1 more articles in the media than Medicus Pharma. MarketBeat recorded 3 mentions for Sunshine Biopharma and 2 mentions for Medicus Pharma. Medicus Pharma's average media sentiment score of 0.93 beat Sunshine Biopharma's score of 0.73 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

42.0% of Sunshine Biopharma shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sunshine Biopharma has higher revenue and earnings than Medicus Pharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
Sunshine Biopharma	$36.31M	0.13	-$5.97M	-$10.15	N/A

Medicus Pharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Medicus Pharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

Summary

Sunshine Biopharma beats Medicus Pharma on 8 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Sunshine Biopharma (NASDAQ:SBFM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Citius Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

In the previous week, Citius Pharmaceuticals had 8 more articles in the media than Sunshine Biopharma. MarketBeat recorded 11 mentions for Citius Pharmaceuticals and 3 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.73 beat Citius Pharmaceuticals' score of -0.46 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.13	-$5.97M	-$10.15	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

Sunshine Biopharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 5,545.16%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 766.40%. Given Sunshine Biopharma's higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Sunshine Biopharma beats Citius Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Scienture?

Scienture (NASDAQ:SCNX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Scienture presently has a consensus price target of $1.50, suggesting a potential upside of 290.52%. Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 5,545.16%. Given Sunshine Biopharma's higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.7% of Scienture shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scienture has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Sunshine Biopharma had 2 more articles in the media than Scienture. MarketBeat recorded 3 mentions for Sunshine Biopharma and 1 mentions for Scienture. Scienture's average media sentiment score of 1.87 beat Sunshine Biopharma's score of 0.73 indicating that Scienture is being referred to more favorably in the media.

Company	Overall Sentiment
Scienture	Very Positive
Sunshine Biopharma	Positive

Sunshine Biopharma has higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	36.68	-$41.51M	-$2.10	N/A
Sunshine Biopharma	$36.31M	0.13	-$5.97M	-$10.15	N/A

Scienture has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Summary

Sunshine Biopharma beats Scienture on 8 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to Intensity Therapeutics?

Sunshine Biopharma (NASDAQ:SBFM) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Intensity Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Intensity Therapeutics	N/A	-116.61%	-94.01%

In the previous week, Intensity Therapeutics had 9 more articles in the media than Sunshine Biopharma. MarketBeat recorded 12 mentions for Intensity Therapeutics and 3 mentions for Sunshine Biopharma. Intensity Therapeutics' average media sentiment score of 0.96 beat Sunshine Biopharma's score of 0.73 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sunshine Biopharma presently has a consensus price target of $70.00, indicating a potential upside of 5,545.16%. Intensity Therapeutics has a consensus price target of $7.00, indicating a potential upside of 54.53%. Given Sunshine Biopharma's higher probable upside, equities research analysts clearly believe Sunshine Biopharma is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Sunshine Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.13	-$5.97M	-$10.15	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A

Summary

Intensity Therapeutics beats Sunshine Biopharma on 9 of the 16 factors compared between the two stocks.

How does Sunshine Biopharma compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Adial Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

Adial Pharmaceuticals presently has a consensus target price of $15.63, suggesting a potential upside of 163.05%. Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 5,545.16%. Given Sunshine Biopharma's higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sunshine Biopharma had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 3 mentions for Sunshine Biopharma and 2 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.94 beat Sunshine Biopharma's score of 0.73 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Adial Pharmaceuticals has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Adial Pharmaceuticals. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Sunshine Biopharma	$36.31M	0.13	-$5.97M	-$10.15	N/A

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sunshine Biopharma beats Adial Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.81M	$12.41B	$7.30B	$12.80B
Dividend Yield	N/A	2.61%	2.54%	10.79%
P/E Ratio	-0.12	782.99	272.76	24.14
Price / Sales	0.13	764.61	630.69	98.18
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.17	12.00	13.14	6.23
Net Income	-$5.97M	$2.83B	$3.47B	$348.07M
7 Day Performance	5.98%	2.04%	1.38%	0.67%
1 Month Performance	-25.30%	6.08%	8.62%	4.84%
1 Year Performance	-91.45%	7.74%	25.90%	16.83%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	3.4628 of 5 stars	$1.24 +8.8%	$70.00 +5,545.2%	-91.9%	$4.81M	$36.31M	N/A	3	News Coverage Short Interest Decrease Gap Up High Trading Volume
MDCX Medicus Pharma	3.0677 of 5 stars	$0.26 -0.8%	$9.00 +3,374.9%	-88.0%	$16.36M	N/A	N/A	N/A	Gap Up
CTXR Citius Pharmaceuticals	2.3823 of 5 stars	$0.60 -1.4%	$5.00 +740.3%	-52.1%	$16.33M	N/A	N/A	20
SCNX Scienture	2.6063 of 5 stars	$0.39 -4.6%	$1.50 +280.7%	-60.6%	$16.18M	$430K	N/A	N/A	Positive News
INTS Intensity Therapeutics	3.2195 of 5 stars	$4.75 -2.8%	$7.00 +47.3%	-37.1%	$15.53M	N/A	N/A	2,021

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. MDCX, CTXR, SCNX, INTS, and ADIL

How does Sunshine Biopharma compare to Medicus Pharma?

Summary

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Summary

How does Sunshine Biopharma compare to Scienture?

Summary

How does Sunshine Biopharma compare to Intensity Therapeutics?

Summary

How does Sunshine Biopharma compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. MDCX, CTXR, SCNX, INTS, and ADIL

How does Sunshine Biopharma compare to Medicus Pharma?

Do analysts prefer MDCX or SBFM?

Does the media refer more to MDCX or SBFM?

Do institutionals and insiders believe in MDCX or SBFM?

Which has preferable valuation and earnings, MDCX or SBFM?

Which has more volatility and risk, MDCX or SBFM?

Is MDCX or SBFM more profitable?

Summary

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Is SBFM or CTXR more profitable?

Does the media prefer SBFM or CTXR?

Which has stronger earnings & valuation, SBFM or CTXR?

Which has more volatility & risk, SBFM or CTXR?

Do insiders and institutionals have more ownership in SBFM or CTXR?

Do analysts prefer SBFM or CTXR?

Summary

How does Sunshine Biopharma compare to Scienture?

Do analysts rate SCNX or SBFM?

Do insiders and institutionals have more ownership in SCNX or SBFM?

Is SCNX or SBFM more profitable?

Does the media prefer SCNX or SBFM?

Which has higher earnings & valuation, SCNX or SBFM?

Which has more volatility and risk, SCNX or SBFM?

Summary

How does Sunshine Biopharma compare to Intensity Therapeutics?

Is SBFM or INTS more profitable?

Does the media refer more to SBFM or INTS?

Do institutionals & insiders believe in SBFM or INTS?

Do analysts rate SBFM or INTS?

Which has more volatility & risk, SBFM or INTS?

Which has better earnings & valuation, SBFM or INTS?

Summary

How does Sunshine Biopharma compare to Adial Pharmaceuticals?

Is ADIL or SBFM more profitable?

Do analysts prefer ADIL or SBFM?

Does the media prefer ADIL or SBFM?

Which has more risk & volatility, ADIL or SBFM?

Which has stronger earnings and valuation, ADIL or SBFM?

Do insiders and institutionals hold more shares of ADIL or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools